Can Type 2 Diabetes Be Reversed? What the Evidence Says About Remission

Type 2 diabetes remission explained: what the DiRECT trial and long-term studies show, who is most likely to achieve it, and why supervision matters.

Remission means blood sugar stays in the normal range without diabetes medicines. It is not a cure — sugar can rise again — but for some people with type 2 diabetes it is a realistic goal. This guide summarises what the major trials show, who is most likely to benefit, and why it must be medically supervised.

Does T2DM remission actually happen? Yes — and modern medications now offer cardio-renal protection alongside glucose control.

Diabetes care has undergone two revolutions in the last decade. First, the DiRECT trial (Lean et al., Lancet 2018) demonstrated that structured weight loss can put T2DM into remission for nearly half of eligible patients — not just improved control, actual remission off medications. Second, the discovery that SGLT2 inhibitors and GLP-1 receptor agonists reduce cardiovascular death, heart failure hospitalisation, and kidney disease progression — often more than they reduce glucose (EMPA-REG, LEADER, DAPA-HF, SELECT trials). Diabetes care in 2026 looks nothing like it did in 2015.

📊

Four evidence pillars for modern diabetes care

From landmark trials over the past decade.

DiRECT trial (Lean et al., Lancet 2018): 46% remission at 12 months, 36% at 24 months (Lean 2019), 13% at 5 years (Lean 2024) with structured 12-week low-calorie diet followed by weight-loss maintenance. Strongest predictor: total weight loss ≥10 kg.

Diabetes Prevention Program (DPP, NEJM 2002, n=3,234): intensive lifestyle intervention reduced progression from prediabetes to T2DM by 58% at 3 years. IDPP-1 (Ramachandran 2006) confirmed 28.5% ARR in Indians with tighter BMI targets.

EMPA-REG OUTCOME (Zinman 2015, NEJM): empagliflozin reduced CV death by 38% in T2DM+CVD. LEADER (Marso 2016): liraglutide reduced MACE by 13%. SELECT (Lincoff 2023): semaglutide reduced MACE by 20% in adults with CVD without diabetes.

DIAMOND (Beck 2017), GOLD (Lind 2017), MOBILE (Martens 2021): continuous glucose monitors reduce HbA1c by 0.4-0.6% AND dramatically reduce hypoglycemia in both T1DM and T2DM. Time-in-Range >70% is now the standard alongside HbA1c.

Why the diabetes playbook has changed

Until 2015, diabetes care focused almost entirely on lowering HbA1c with sulfonylureas or basal insulin, and everyone accepted lifelong medications with slowly worsening control. Two breakthroughs changed that. First, DiRECT definitively showed that many T2DM patients can achieve remission — full normalisation of glucose off all diabetes medications — with structured weight loss delivered in primary care. Second, cardiovascular outcome trials mandated by the FDA after 2008 revealed that SGLT2 inhibitors and GLP-1 receptor agonists don't just lower glucose — they meaningfully reduce cardiovascular and kidney events, sometimes independent of glycemic effect.

Modern guidelines (ADA Standards of Care 2025, EASD-ADA Consensus 2022, NICE NG28 2022, RSSDI 2024) now recommend a two-track approach: (1) for those diagnosed <6 years and interested, offer a remission programme first; (2) for everyone, select medications not only for HbA1c but for organ protection — SGLT2i for heart failure or CKD, GLP-1RA (especially semaglutide, tirzepatide) for ASCVD or obesity. Metformin remains the first oral in most patients, but the "SGLT2i or GLP-1RA next" question has been replaced by "SGLT2i AND GLP-1RA if appropriate" for many.

delivery holds all these gains for management. Telemedicine has been validated in ADA Standards since 2021. CGM data reviews are, if anything, easier — sensors upload to cloud dashboards your diabetologist reviews in real time. NABL-certified home phlebotomy handles HbA1c, kidney panels and lipids without you leaving home. Retinal photos can now be captured by trained retinographers at home via portable fundus cameras. What still requires in-person: the annual dilated eye exam (formal ophthalmology), the annual foot exam with monofilament testing, and any acute complications.

💡 The bottom line: If you were diagnosed with T2DM in the last 6 years, HbA1c <10%, BMI ≥25, and can commit to a structured 12-week programme, you have a real chance of remission — the strongest predictor is total weight loss in the first 3 months. If you have established diabetes, modern SGLT2i + GLP-1RA combinations offer meaningful cardio-renal protection beyond glucose control. Either way, tight control while avoiding hypoglycemia (informed by CGM data) is the standard, not the aspiration.

Sources: Lean MEJ et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018;391:541-551 · Lean MEJ et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019;7:344-355 · Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403 · Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med 2015;373:2117-28 · Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-22 · Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-2232 · ADA Standards of Care in Diabetes 2025.

The evidence that modern diabetes care changes lives.

Beyond short-term HbA1c reduction, does modern diabetes care actually change long-term outcomes — years of life, quality of life, complications avoided, remission achieved? Landmark trials with 5-30 year follow-ups answer this — and the answer is a resounding yes.

🏆

Durable T2DM Remission (DiRECT 5-year)

Of patients who achieved 12-month remission on DiRECT VLCD protocol, 13% remained in full remission at 5 years — plus many others had significantly improved metabolic health without full remission. Weight-loss maintenance is the key predictor.

Lean MEJ et al. DiRECT 5-year follow-up. Lancet Diabetes Endocrinol 2024.

📉

UKPDS Legacy Effect (30-year)

Early intensive glucose control in newly-diagnosed T2DM produces mortality benefit that persists 30+ years later — even after glycemic control equalises. Metformin specifically reduced diabetes-related mortality by 42% in overweight T2DM.

UKPDS 33 & 34 (Lancet 1998) · Holman UKPDS Legacy Effect (NEJM 2008) · 30-yr follow-up 2023.

🎯

ACCORD & ADVANCE — Tight Control Nuance

Very intensive glucose lowering (HbA1c <6.5%) in older T2DM with CV disease showed no macrovascular benefit and possible mortality harm (ACCORD 2008). Modern targets are individualised — tighter for younger/newer T2DM, looser for older/complex.

ACCORD Study Group. NEJM 2008;358:2545 · ADVANCE. NEJM 2008;358:2560.

��

Cardiovascular Mortality (EMPA-REG)

Empagliflozin reduced cardiovascular death by 38% and all-cause mortality by 32% in T2DM patients with established cardiovascular disease over 3.1 years median follow-up — the first oral diabetes drug to show mortality benefit.

Zinman B et al. EMPA-REG OUTCOME. NEJM 2015;373:2117-28.

💗

LEADER (Liraglutide CV Outcome)

Liraglutide reduced MACE (CV death, non-fatal MI, non-fatal stroke) by 13% and CV death alone by 22% in T2DM patients at high CV risk. Established GLP-1RA class benefit for CV protection.

Marso SP et al. LEADER. NEJM 2016;375:311-22.

🧬

SUSTAIN-6 (Semaglutide CV Outcome)

Semaglutide reduced MACE by 26% in T2DM+CVD over 2.1 years. Established semaglutide as CV-protective. SELECT trial (2023) then extended to adults with obesity WITHOUT diabetes — 20% MACE reduction.

Marso SP et al. SUSTAIN-6. NEJM 2016 · Lincoff AM et al. SELECT. NEJM 2023.

⚖️

Bariatric Surgery Durability (STAMPEDE 5-yr)

Roux-en-Y bypass produced 40% durable T2DM remission at 5 years vs 5% with intensive medical therapy alone in BMI ≥35 with T2DM. Sleeve gastrectomy 29% remission at 5 years.

Schauer PR et al. STAMPEDE 5-year outcomes. NEJM 2017;376:641-651.

👁

Complications Prevention (DCCT/EDIC 30-yr)

In Type 1 diabetes, early intensive glucose control (via multiple daily injections + monitoring) reduced retinopathy progression by 76%, neuropathy by 60%, and albuminuria by 39% — with benefit persisting 30 years after DCCT ended.

DCCT Research Group (NEJM 1993) · EDIC follow-up 30-year (Diabetes Care 2023).

The studies that built modern diabetes care.

Every clinical claim on this page traces back to specific pieces of research. Below is a curated timeline of the most influential diabetes trials — the ones that changed how diabetes is understood, diagnosed, and treated. Use it to check the evidence base of any claim, anywhere.

Foundational Glucose-Control Trials

Cardiovascular Outcome Trials (CVOTs) - The Revolution

Remission & Weight-Loss Trials

Technology & CGM Trials

This is the evidence base we practice from